Welcome to the e-CCO Library!

search
Search by: 
Year: Category:
DOP016: Postoperative clinical recurrence is not different in Crohn’s disease patients classified as i2 on the Rutgeerts score with lesions confined to the ileocolonic anastomosis than in those with lesions of the neoterminal ileum
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Bayart*1, N. Duveau1, M. Nachury1, P. Zerbib1, R. Gerard1, J. Branche1, V. Maunoury1, A. Boruchowicz2, M. Boualit2, J.-E. Laberenne3, O. Manolache3, G. Pineton de Chambrun4, B. Pariente1

Created: Friday, 22 February 2019, 9:49 AM
DOP016: Postoperative clinical recurrence is not different in Crohn’s disease patients classified as i2 on the Rutgeerts score with lesions confined to the ileocolonic anastomosis than in those with lesions of the neo-terminal ileum
Year: 2016
Source: ECCO'16 DOP
Authors: Bayart P.
post operative management; disease activity indices
Files: 1
DOP017: Colectomy Free Survival is Independent of Initial Infliximab Dosing Strategy in Hospitalised Ulcerative Colitis Patients
Year: 2016
Source: ECCO'16 DOP
Authors: Shah S.
Ulcerative Colitis, infliximab, colectomy
Files: 1
DOP017: Colectomy-free survival is independent of initial infliximab dosing strategy in hospitalised ulcerative colitis patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Shah*, S. Naymagon, B. Sands, B. Cohen, M. Dubinsky

Created: Friday, 22 February 2019, 9:49 AM
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Harrow1,2*, N. McCarthy1, A. Stagg1, J. Lindsay1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn's Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Harrow Paul
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP017: Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bots S.*1, Hoekman D.1,2, Benninga M.2, Ponsioen C.1, Smeets H.3, D'Haens G.1, Löwenberg M.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP017: Patterns of anti-TNF use and associated treatment outcomes in Inflammatory Bowel Disease patients: Results from an analysis of Dutch health insurance claims data
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bots S.
Health economic analysis, Adalimumab, Anti-TNF agents, Infliximab
Files: 1
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Creyns1*, B. Verstockt2,3, J. Cremer1, M. Ferrante2,3, S. Vermeire2,3, C. Jan1, G. Van Assche2,3, C. Breynaert1

Created: Thursday, 21 February 2019, 9:14 AM
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Creyns Brecht
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7

Created: Wednesday, 20 February 2019, 10:36 AM
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADA
Year: 2017
Source: ECCO'17 Barcelona
Authors: Skup M.
Adalimumab, Arthralgia, Pyoderma gangrenosum, Other extraintestinal manifestations
Files: 1
DOP018: Long-term follow-up after ileorectal anastomosis in Ulcerative Colitis (UC) identified factors associated with rectal outcome: a multicenter retrospective cohort of 343 patients from the GETAID/GETAID Surgery
Year: 2016
Source: ECCO'16 DOP
Authors: Uzzan M.
colectomy, Ulcerative Colitis, ileorectal anastomosis
Files: 1
DOP018: Long-term follow-up after ileorectal anastomosis in ulcerative colitis (UC) identified factors associated with rectal outcome: a multicentre retrospective cohort of 343 patients from the GETAID/GETAID Surgery
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Uzzan*1, J. Cosnes2, N. Oubaya3, A. Amiot4, N. Gault3, J.-M. Gornet5, P. Seksik2, S. Nancey6, E. Cotte7, M. Allez5, D. Laharie8, N. De angelis4, M. Nachury9, A.-L. Pelletier10, V. Abitbol11, M. Fumery12, A. Brouquet13, A. Buisson14, R. Altwegg15, Y. Panis16, X. Treton1

Created: Friday, 22 February 2019, 9:49 AM
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feagan B.G.*1, Sandborn W.J.2, Colombel J.-F.3, O'Byrne S.4, Khalid J.M.5, Brayshaw N.6, Geransar P.7, Rubin D.T.8

Created: Wednesday, 20 February 2019, 10:36 AM
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s Disease: A GEMINI 2 post hoc analysis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Feagan B.
Crohn's disease, Vedolizumab, Other extraintestinal manifestations
Files: 1
DOP019: Efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. López García1, M. Rovira2, A. Jauregui Amezaga1, P. Marin3, A. Salas1, S. Pinó Donnay1, R. Barastegui1, F. Feu1, J. Elizalde1, F. Fernández-Avilés2, C. Martínez4, G. Gutierrez2, L. Rosiñol2, E. Carreras2, A. Urbano2, M. Lozano3, J. Cid3, M. Suárez-Lledó2, J. Mensa5, J. Rimola6, S. Rodriguez6, M. C. Masamunt1, D. Comas1, A. Ramirez Morros1, M. Gallego1, I. Ordás1, J. Panés1, E. Ricart*1

Created: Friday, 22 February 2019, 9:49 AM
DOP019: Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease
Year: 2016
Source: ECCO'16 DOP
Authors: Ricart E.
stem cell transplantation/therapy, Crohn's Disease
Files: 1
DOP019: Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Burisch1*, V. Andersen2,3, S. Čuković-Čavka4, P.L. Lakatos5, R. D'Inca6, F. Magro7,8,9, N. Arebi10, L. Kievit11, I. Kaimakliotis12, D. Valpiani13, K.H. Katsanos14, Z. Vegh5, J.F. Dahlerup15, M. Fumery16, N. Pedersen17, J. Halfvarson18, E. Belousova19, K.R. Nielsen20, S. Turcan21, P. Ellul22, L. Kupcinskas23, P. Oksanen24, D. Duricova25, M. Giannotta26, A. Goldis27, V. Hernandez28, R. Salupere29, S. Odes30, E. Langholz31, P. Munkholm1, Epi-IBD study group

Created: Thursday, 21 February 2019, 9:14 AM
DOP019: Immunomodulators reduce the risk of surgery and hospitalization in Crohn’s Disease in a prospective European population-based inception cohort – the Epi-IBD cohort
Year: 2018
Source: ECCO'18 Vienna
Authors: Burisch Johan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1